Hims & Hers Health, Inc. (NYSE:HIMS) Receives $20.21 Consensus PT from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $20.21.

A number of research analysts recently issued reports on the company. Truist Financial boosted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Piper Sandler restated a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Finally, TD Cowen lifted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $18.85 on Friday. The company has a market capitalization of $4.05 billion, a P/E ratio of 235.56 and a beta of 1.06. The company has a fifty day moving average of $17.94 and a 200-day moving average of $18.01. Hims & Hers Health has a 52-week low of $5.76 and a 52-week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.03) earnings per share. As a group, analysts forecast that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Insider Activity

In related news, insider Soleil Boughton sold 2,334 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the sale, the insider now owns 164,475 shares in the company, valued at approximately $2,845,417.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the transaction, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 2,334 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the sale, the insider now owns 164,475 shares in the company, valued at approximately $2,845,417.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 858,665 shares of company stock valued at $15,148,890 over the last three months. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after buying an additional 46,541 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $155,000. State of Michigan Retirement System bought a new position in shares of Hims & Hers Health during the 1st quarter valued at approximately $2,785,000. Lake Street Private Wealth LLC purchased a new stake in Hims & Hers Health during the 1st quarter valued at $650,000. Finally, Principal Financial Group Inc. lifted its position in Hims & Hers Health by 17.9% in the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock worth $258,000 after buying an additional 2,525 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.